Lupin Acquires UK-Based Renascience Pharma for £12.3 Mn
Lupin stated that the acquisition aligns with its strategy to expand its branded medicine portfolio in the UK.
Indian pharmaceutical major Lupin has announced the acquisition of Renascience Pharma Limited, a UK-based specialty pharmaceutical company, through its wholly owned subsidiary, Lupin Healthcare (UK) Limited.
The transaction, valued at £12.3 million, grants Lupin full ownership of Renascience and its portfolio of four specialty pharmaceutical products.
Founded in 2015, Renascience supplies niche-branded bio-generic medicines catering to primary and secondary care in the UK.
Its key products include injectable treatments for infectious diseases, ear drops for pain management, and an oral therapy used in cardiology and nephrology.
Notably, XAQUA (a diuretic) and OTIGO (an ear drop formulation) account for nearly 90% of the company's revenue.
Renascience reported a turnover of £3.51 million for the financial year ending February 2025, marking significant growth from £1.87 million in FY24 and £0.72 million in FY23.
Strategic Expansion in Branded Pharmaceuticals
Lupin stated that the acquisition aligns with its strategy to expand its branded medicine portfolio in the UK.
The company has been focusing on addressing unmet medical needs in the region and strengthening its presence in specialty therapeutic segments.
Fabrice Egros, President of Corporate Development at Lupin, emphasized that the acquisition supports Lupin's commitment to providing accessible and sustainable healthcare solutions.
Eric Che, Co-founder and Director of Renascience expressed confidence that the acquisition will help expand the company's market reach and build upon its existing business.
The transaction does not require regulatory approvals and was completed alongside the execution of the definitive agreement. Renascience Pharma will operate as a wholly owned subsidiary of Lupin Healthcare (UK) Limited with this acquisition.
Lupin Healthcare focuses on antiretrovirals, women's health, neuroscience, and respiratory treatments. It works in partnership with the UK's National Health Service (NHS) to deliver pharmaceutical solutions in these areas.
Stay tuned for more such updates on Digital Health News.
